Mizuho raised the firm’s price target on Abbott to $115 from $110 and keeps a Neutral rating on the shares post the Q2 report. The results were driven by broad-based strength across business units and highlighted by 14% organic growth in medical devices and further recovery in pediatric nutrition from the mid-2022 recalls, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ABT:
- Abbott (NYSE: ABT) Stock Gains on Q2 Beat; Lifts 2023 Revenue Forecast
- Abbott upgraded to Peer Perform from Underperform at Wolfe Research
- Abbott saw ‘very strong growth’ across all four sectors in Q2
- Abbott sees Q3 adjusted EPS about $1.10, consensus $1.11
- Abbott reports Q2 worldwide Medical Devices sales up 13.5% on reported basis